Bruker (BRKR) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 17.4% year-over-year to $800.7M, driven by strong organic growth and significant contributions from recent acquisitions in spatial biology, molecular diagnostics, and lab automation.

• Non-GAAP EPS for Q2 2024 was $0.52, up 4.0% year-over-year; GAAP EPS was $0.05, down sharply due to acquisition-related costs and higher operating expenses.

• Major acquisitions in H1 2024 included Chemspeed, ELITech, and NanoString, all performing at or above expectations and accelerating portfolio transformation.

• Net income and operating margin declined due to acquisition and restructuring costs, with Q2 2024 non-GAAP margin at 13.8%, down 150 bps year-over-year.

• Despite soft market conditions and headwinds in China and biopharma, the company executed well on Project Accelerate 2.0 and continued to outpace the broader market.

Financial highlights

• Q2 2024 reported revenue was $800.7M (+17.4% YoY), with organic growth of 7.4% and CER growth of 18.5%.

• Q2 2024 non-GAAP gross margin was 51.3% (+40 bps YoY); non-GAAP operating income was $110.7M (+6.3% YoY).

• H1 2024 revenue was $1,522.4M (+11.4% YoY), with organic growth of 4.5%; non-GAAP EPS was $1.05, down 8.7% YoY.

• Q2 2024 free cash flow was $(25.1)M, with H1 2024 free cash flow at $(24.7)M, reflecting acquisition expenses and seasonality.

• Cash and cash equivalents at June 30, 2024, were $169.7M, down from $488.3M at year-end 2023; total debt increased to $2,158.4M.

Outlook and guidance

• FY 2024 revenue guidance raised to $3.38–$3.44B (+14–16% YoY), with organic growth of 5–7% and M&A tailwind of ~10%.

• FY 2024 non-GAAP EPS guidance is $2.59–$2.64, implying flat to low single-digit growth despite EPS dilution from acquisitions.

• Non-GAAP operating margin expected to decline ~240 bps to ~16%, with >50 bps organic margin increase offset by >300 bps M&A and FX headwinds.

• Q3 2024 organic revenue expected to grow mid-single digits; Q3 non-GAAP EPS to be down YoY but up sequentially, with Q4 EPS growth re-accelerating.

• Management expects continued revenue growth and margin expansion over the next three years, despite ongoing restructuring and integration costs.